MX392270B - Oxisteroles sustituidos en c7 y metodos de uso de los mismos. - Google Patents
Oxisteroles sustituidos en c7 y metodos de uso de los mismos.Info
- Publication number
- MX392270B MX392270B MX2019003724A MX2019003724A MX392270B MX 392270 B MX392270 B MX 392270B MX 2019003724 A MX2019003724 A MX 2019003724A MX 2019003724 A MX2019003724 A MX 2019003724A MX 392270 B MX392270 B MX 392270B
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- methods
- substituted oxysterols
- compounds
- oxysterols
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402797P | 2016-09-30 | 2016-09-30 | |
| US201662402789P | 2016-09-30 | 2016-09-30 | |
| PCT/US2017/054657 WO2018064649A1 (en) | 2016-09-30 | 2017-09-30 | C7 substituted oxysterols and methods as nmda modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019003724A MX2019003724A (es) | 2019-09-04 |
| MX392270B true MX392270B (es) | 2025-03-24 |
Family
ID=60117790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003724A MX392270B (es) | 2016-09-30 | 2017-09-30 | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11149056B2 (https=) |
| EP (1) | EP3519422B1 (https=) |
| JP (3) | JP7149266B2 (https=) |
| CN (3) | CN115850361B (https=) |
| AU (1) | AU2017337121B2 (https=) |
| CA (1) | CA3038900A1 (https=) |
| ES (1) | ES2935057T3 (https=) |
| MA (1) | MA46351A (https=) |
| MX (1) | MX392270B (https=) |
| PT (1) | PT3519422T (https=) |
| WO (1) | WO2018064649A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230747T1 (hr) | 2011-09-08 | 2024-01-05 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihova uporaba |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PL3319611T3 (pl) | 2015-07-06 | 2021-07-12 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| MX382122B (es) | 2015-07-06 | 2025-03-13 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| EP3436022B1 (en) | 2016-04-01 | 2022-03-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018009867A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PT3519422T (pt) | 2016-09-30 | 2022-12-05 | Sage Therapeutics Inc | Oxisteróis substituídos em c7 e métodos como moduladores nmda |
| CA3041088C (en) | 2016-10-18 | 2024-05-21 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| DK4105223T3 (da) | 2016-10-18 | 2025-07-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| IL308273A (en) * | 2021-05-04 | 2024-01-01 | Sage Therapeutics Inc | Neuroactive steroids for the treatment of mild cognitive impairment associated with Parkinson's disease |
| EP4405370A1 (en) * | 2021-09-22 | 2024-07-31 | Sage Therapeutics, Inc. | Deuterated positive nmda-modulating compounds and methods of use thereof |
| EP4671260A3 (en) * | 2024-06-28 | 2026-03-04 | Industriale Chimica S.r.l. | Process for the preparation of (3-beta,24s)-25,25,25-trifluoro-3-methyl-26,27-dinorergost-5-ene-3,24-diol |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2259698A (en) | 1938-05-07 | 1941-10-21 | Rare Chemicals Inc | Physiologically effective substance and process of preparing same |
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US2673206A (en) | 1950-06-07 | 1954-03-23 | Schering Corp | 25-ethinyl steroids |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| JPS5324071B2 (https=) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| US4183852A (en) | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| US4174345A (en) | 1978-08-01 | 1979-11-13 | Kaiser Emil T | Synthesis of steroids |
| US4269777A (en) | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| US4358406A (en) | 1981-07-27 | 1982-11-09 | Wisconsin Alumni Research Foundation | 26,26,26,27,27,27-Hexafluoro-1α,25-dihydroxycholecalciferol and process for preparing same |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| ATE45347T1 (de) | 1985-05-30 | 1989-08-15 | Taisho Pharmaceutical Co Ltd | Vitamin d3-derivate. |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| AU609927B2 (en) | 1987-08-25 | 1991-05-09 | Kelvin W. Gee | Compositions and methods for alleviating stress, anxiety and seizure activity |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| DE4338316A1 (de) | 1993-11-10 | 1995-05-11 | Jenapharm Gmbh | Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| KR100338287B1 (ko) | 1994-02-14 | 2002-11-30 | 푸르듀 파머 리미티드 | 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난 |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5595996A (en) * | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| FI972202L (fi) | 1994-11-23 | 1997-07-17 | Cocensys Inc | Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun |
| JPH08268917A (ja) | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| RU2194712C2 (ru) | 1995-06-06 | 2002-12-20 | Коукенсис, Инк. | НЕЙРОАКТИВНЫЕ СТЕРОИДЫ, ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ НАРУШЕНИЙ, СПОСОБ ИНДУКЦИИ СНА И СПОСОБ ИНДУКЦИИ АНЕСТЕЗИИ С ИХ ИСПОЛЬЗОВАНИЕМ, СПОСОБ МОДУЛИРОВАНИЯ КОМПЛЕКСА РЕЦЕПТОР ГАМКa-ХЛОРИДНЫЙ ИОНОФОР |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| IL122609A0 (en) | 1995-06-23 | 1998-08-16 | Novo Nordisk As | Meiosis regulating compounds |
| JP4313435B2 (ja) | 1995-07-24 | 2009-08-12 | トラスティーズ オブ ボストン ユニバーシティー | プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| AU3068497A (en) | 1996-05-06 | 1997-11-26 | Bionumerik Pharmaceuticals, Inc. | Process for preparing 27-hydroxy cholesterol and related derivatives |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| US7012069B2 (en) | 2001-05-03 | 2006-03-14 | Arch Development Corporation | Liver X receptor agonists |
| CA2331299A1 (en) | 1998-05-11 | 1999-11-18 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
| KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
| UA73736C2 (en) | 1999-04-29 | 2005-09-15 | Euro Celtic S A | Method for alleviating or preventing insomnia and inducing anesthesia |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1111167C (zh) | 1999-10-22 | 2003-06-11 | 中国科学院上海有机化学研究所 | 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途 |
| CN1098273C (zh) * | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| CA2466033A1 (en) | 2001-11-08 | 2003-05-15 | The University Of Chicago | Method of treating disorder related to high cholesterol concentration |
| JP2005511713A (ja) | 2001-12-07 | 2005-04-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | 加齢性黄斑変性についての処置 |
| PL213697B1 (pl) | 2002-03-27 | 2013-04-30 | Phytopharm Plc | Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych |
| KR101130212B1 (ko) | 2002-03-27 | 2012-04-13 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 사용법 |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| WO2004055201A2 (en) | 2002-12-13 | 2004-07-01 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| GB0403889D0 (en) * | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US20070032464A1 (en) | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| JP2008518935A (ja) | 2004-11-01 | 2008-06-05 | セオ ホン ユー | 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物 |
| US9670244B2 (en) | 2006-02-27 | 2017-06-06 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| CN101164540A (zh) | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
| GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| US8273747B2 (en) | 2006-11-02 | 2012-09-25 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| WO2009073186A1 (en) | 2007-12-03 | 2009-06-11 | The Regents Of The University Of California | Oxsterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
| JP2008268917A (ja) | 2007-03-26 | 2008-11-06 | Kyocera Mita Corp | 液体現像剤循環装置および画像形成装置 |
| JP5587184B2 (ja) | 2007-06-20 | 2014-09-10 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 繊維症阻害剤としての置換ｎ−アリールピリジノン |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| EP2207542A2 (en) | 2007-11-06 | 2010-07-21 | N.V. Organon | A method of hormone suppression in humans |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| JP2011510084A (ja) | 2008-01-25 | 2011-03-31 | メルク・シャープ・エンド・ドーム・コーポレイション | キノリジジノン系ｍ１受容体陽性アロステリック調節剤 |
| NZ589764A (en) | 2008-05-09 | 2012-10-26 | Univ Emory | NMDA receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| EP2459581A4 (en) | 2009-07-29 | 2012-12-26 | Univ Chicago | LIVER X-RECEPTOR AGONISTS |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| WO2012142039A1 (en) | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| EP2714081A4 (en) | 2011-05-27 | 2015-09-09 | Cytocure Llc | METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| HRP20230747T1 (hr) | 2011-09-08 | 2024-01-05 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihova uporaba |
| PL2763979T3 (pl) | 2011-10-07 | 2019-06-28 | Takeda Pharmaceutical Company Limited | Związki 1-arylokarbonyl-4-oksy-piperydynowe użyteczne do leczenia chorób neurodegeneracyjnych |
| CN119192266A (zh) | 2011-10-14 | 2024-12-27 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| WO2013163455A2 (en) | 2012-04-25 | 2013-10-31 | The Regents Of The University Of California | A drug screening platform for rett syndrome |
| US20140149272A1 (en) | 2012-08-17 | 2014-05-29 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| MX365644B (es) | 2012-12-18 | 2019-06-10 | Univ Washington | Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos. |
| WO2014115167A2 (en) | 2013-01-23 | 2014-07-31 | Sphaera Pharma Pvt. Ltd. | Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion |
| KR20150110787A (ko) | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| CN105164161A (zh) | 2013-03-13 | 2015-12-16 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| JP2016531852A (ja) | 2013-09-25 | 2016-10-13 | ヴァン アンデル リサーチ インスティテュート | 非常に強力なグルココルチコイド |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| SG11201702799UA (en) | 2014-10-07 | 2017-05-30 | Sage Therapeutics Inc | Neuroactive compounds and methods of use thereof |
| PL3319611T3 (pl) | 2015-07-06 | 2021-07-12 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| MX382122B (es) | 2015-07-06 | 2025-03-13 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| AU2016289965B2 (en) | 2015-07-06 | 2021-09-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| EP3436022B1 (en) * | 2016-04-01 | 2022-03-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018009867A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| PT3519422T (pt) * | 2016-09-30 | 2022-12-05 | Sage Therapeutics Inc | Oxisteróis substituídos em c7 e métodos como moduladores nmda |
| CA3041088C (en) | 2016-10-18 | 2024-05-21 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| DK4105223T3 (da) | 2016-10-18 | 2025-07-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
| BR112019027458A2 (pt) | 2017-06-23 | 2020-07-07 | Intercept Pharmaceuticals, Inc. | métodos e intermediários para a preparação de derivados de ácidos biliares |
| AU2018364659A1 (en) | 2017-11-10 | 2020-05-28 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
-
2017
- 2017-09-30 PT PT177847704T patent/PT3519422T/pt unknown
- 2017-09-30 CN CN202211226669.3A patent/CN115850361B/zh active Active
- 2017-09-30 CA CA3038900A patent/CA3038900A1/en active Pending
- 2017-09-30 JP JP2019517289A patent/JP7149266B2/ja active Active
- 2017-09-30 MX MX2019003724A patent/MX392270B/es unknown
- 2017-09-30 EP EP17784770.4A patent/EP3519422B1/en active Active
- 2017-09-30 WO PCT/US2017/054657 patent/WO2018064649A1/en not_active Ceased
- 2017-09-30 CN CN201780072617.6A patent/CN110023323A/zh active Pending
- 2017-09-30 AU AU2017337121A patent/AU2017337121B2/en active Active
- 2017-09-30 CN CN202511041222.2A patent/CN121085986A/zh active Pending
- 2017-09-30 US US16/338,315 patent/US11149056B2/en active Active
- 2017-09-30 MA MA046351A patent/MA46351A/fr unknown
- 2017-09-30 ES ES17784770T patent/ES2935057T3/es active Active
-
2021
- 2021-09-15 US US17/476,153 patent/US11926646B2/en active Active
-
2022
- 2022-01-13 JP JP2022003714A patent/JP2022036260A/ja not_active Withdrawn
-
2024
- 2024-02-01 US US18/430,056 patent/US12331070B2/en active Active
- 2024-03-15 JP JP2024041201A patent/JP2024069502A/ja active Pending
-
2025
- 2025-05-13 US US19/206,490 patent/US20250388622A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3519422B1 (en) | 2022-08-31 |
| US12331070B2 (en) | 2025-06-17 |
| AU2017337121B2 (en) | 2022-01-27 |
| JP2022036260A (ja) | 2022-03-04 |
| US11149056B2 (en) | 2021-10-19 |
| US20240300995A1 (en) | 2024-09-12 |
| JP7149266B2 (ja) | 2022-10-06 |
| NZ752193A (en) | 2024-11-29 |
| MA46351A (fr) | 2021-06-02 |
| CN115850361A (zh) | 2023-03-28 |
| JP2019529495A (ja) | 2019-10-17 |
| BR112019006365A2 (pt) | 2019-08-06 |
| US20220081465A1 (en) | 2022-03-17 |
| PT3519422T (pt) | 2022-12-05 |
| US20250388622A1 (en) | 2025-12-25 |
| AU2017337121A1 (en) | 2019-04-18 |
| MX2019003724A (es) | 2019-09-04 |
| CA3038900A1 (en) | 2018-04-05 |
| EP3519422A1 (en) | 2019-08-07 |
| CN110023323A (zh) | 2019-07-16 |
| JP2024069502A (ja) | 2024-05-21 |
| US11926646B2 (en) | 2024-03-12 |
| WO2018064649A1 (en) | 2018-04-05 |
| US20200024300A1 (en) | 2020-01-23 |
| ES2935057T3 (es) | 2023-03-01 |
| CN115850361B (zh) | 2026-04-07 |
| CN121085986A (zh) | 2025-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX382122B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| CY1124404T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων | |
| MX2022005160A (es) | Oxisteroles y metodos de uso de los mismos. | |
| CY1125230T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| MX2020007265A (es) | Derivados de rapamicina. | |
| MX2018003432A (es) | Compuestos heterociclicos y usos de los mismos. | |
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| EA201991700A1 (ru) | Селективные ингибиторы jak1 | |
| EA202090688A1 (ru) | Бис-амидные соединения, активирующие саркомер, и варианты их применения | |
| JOP20210004A1 (ar) | عوامل تحلّل مستقبلات الإستروجين الانتقائية | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| NZ735648A (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| MX376283B (es) | Compuestos de imidazopiridazina. | |
| EA202090978A1 (ru) | Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции | |
| UA130690C2 (uk) | Інгібітори о-глікопротеїн-2-ацетамідо-2-деокси-3-d-глюкопіранозидази | |
| MX373162B (es) | Piridopirimidinonas y utilización de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda). | |
| JOP20200030A1 (ar) | مركب خماسي الحلقة | |
| JO3742B1 (ar) | مركب بيرانو داي بيريدين | |
| CY1123185T1 (el) | Παραγωγα ινδολιου |